Survival Impact of an On-Site Medicalization Program in the Control of COVID-19 Outbreaks in 11 Nursing Homes
Abstract
:1. Introduction
2. Patients and Methods
3. Reference Population and Inclusion Criteria
4. Medicalization Program Characterization
- The areas of the residence were divided into clean and contaminated areas. A “clean area” with common areas and rooms for uninfected residents and a contaminated area also with rooms and common areas where affected residents were transferred were established. All members of the work team were required to wear personal protective equipment when staying within the contaminated area.
- 2.
- Diagnostic testing during the first wave was performed using a SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) panel for the detection of SARS-CoV-2 and a lateral flow serologic technique with fingerstick blood samples for the identification of specific antibodies against SARS-CoV-2. During the second wave, a diagnostic test was performed using a SARS-CoV-2 real-time reverse transcription polymerase chain reaction (rRT-PCR) panel, lateral flow immunoassay SARS-CoV-2 antigen detection test, or both for the detection of SARS-CoV-2.
- 3.
- The healthcare worker provision involved a round-the-clock clinical care service provided by mixed teams of physicians and nurses, covering all seven days of the week. These teams were composed of healthcare professionals from primary care, the hospital’s Internal Medicine Department, and emergency departments. A total of 60 healthcare workers were mobilized for this effort, consisting of 35 physicians and 25 nurses. They underwent specialized training for the management and treatment of COVID-19 patients. To ensure safety, a clear division was maintained between personnel working in the clean area and those operating in the contaminated area. Adequate clinical care was provided, and any staff members who tested positive for acute SARS-CoV-2 infection were promptly isolated and quarantined until they received a negative result from a weekly nasopharyngeal swab PCR test, starting from the first day they exhibited no symptoms.
- 4.
- A standardized clinical management and treatment algorithm was developed, along with a uniform communication protocol to provide daily updates to relatives via phone regarding the clinical condition of both affected and unaffected residents. Electronic admission was implemented for all residents with confirmed SARS-CoV-2 infection. This electronic system enabled healthcare providers to access and update electronic health records, request blood extractions, and prescribe medications as if the patients were being treated within a hospital setting.
- 5.
- A thorough epidemiological investigation was conducted, including continuous monitoring to trace the origin and progression of the outbreaks. Additionally, there was an adequate supply of essential equipment, disposable items, and medications. This supply encompassed materials for blood extractions, intravenous and subcutaneous lines, intravenous fluids, oxygen therapy equipment, electrocardiographs, a portable ultrasound machine, and various hospital medications, such as antiviral agents and intravenous drugs, among other essential provisions.
5. Clinical Algorithm and Treatment Protocols
5.1. Active Standard Care
5.2. Advanced Palliative Care
5.3. Medical Monitoring, Referrals, and Medical Discharge
6. Statistical Analysis
7. Ethical Aspects
8. Results
9. Discussion
What Can We Say That We Have Learned from the MP?
- The importance of nursing homes in the health system, which, although they are on the border between health and social care, are key elements that must be addressed with an adequate response from the health system, especially in the face of serious threats such as the case of a pandemic like the one we have experienced.
- The health system must learn to redistribute material and human resources according to the needs of the population, moving from hospital immobility and learning to go out when necessary, adapting to the requirements of the moment and of the population. One of the functions and objectives of the medicalization of the residences has been to avoid the further collapsing of hospital resources, since they were already in a precarious situation. The purpose was to treat patients (as far as possible) within the care homes themselves and transfer only the really necessary cases. Thus, several hundred patients would have been referred to the hospital in this period if the residences had not been medicalized, with the consequent risk of collapse of the emergency department and hospitalization wards, which were already overwhelmed.
- Collaborative efforts between primary care and the hospital are far more potent than the sum of the work of both separately. Although there are already experiences where both levels work synchronously, despite the difficulties, these tend to be isolated experiences that start from the professionals themselves who join forces and improve patient care. However, this MP project shows that in situations of maximum difficulty and lack of resources, joint work between primary care and hospitals is the best and most efficient way to respond to a crisis that threatens an entire health system due to a global pandemic.
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. COVID-19 Weekly Epidemiological Update Edition 124, as of 4 January 2023. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---4-january-2023 (accessed on 4 January 2023).
- European Center for Disease Control and Prevention. COVID-19 Situation Update for the EU/EEA, as of 1 July 2021. Available online: https://www.ecdc.europa.eu/en/cases-2019-ncov-eueea (accessed on 4 January 2023).
- Adams, M.L.; Katz, D.L.; Grandpre, J. Population-based estimates of chronic conditions affecting risk for complications from Coronavirus disease, United States. Emerg. Infect. Dis. 2020, 26, 1831–1833. [Google Scholar] [CrossRef]
- Williamson, E.J.; Walker, A.J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C.E.; Curtis, H.J.; Mehrkar, A.; Evans, D.; Inglesby, P.; et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020, 584, 430–436. [Google Scholar] [CrossRef]
- Rosenbaum, L. Facing Covid-19 in Italy—Ethics, Logistics, and Therapeutics on the Epidemic’s Front Line. N. Engl. J. Med. 2020, 382, 1873–1875. [Google Scholar] [CrossRef]
- Peterson, A.; Largent, E.A.; Karlawish, J. Ethics of reallocating ventilators in the covid-19 pandemic. BMJ 2020, 369, m1828. [Google Scholar] [CrossRef]
- Ouslander, J.G.; Grabowski, D.C. COVID-19 in Nursing Homes: Calming the Perfect Storm. J. Am. Geriatr. Soc. 2020, 68, 2153–2162. [Google Scholar] [CrossRef]
- Su, Z.; McDonnell, D.; Li, Y. Why is COVID-19 more deadly to nursing home residents? QJM Int. J. Med. 2021, 114, 543–547. [Google Scholar] [CrossRef]
- Dumyati, G.; Gaur, S.; Nace, D.A.; Jump, R.L. Does Universal Testing for COVID-19 Work for Everyone? J. Am. Med. Dir. Assoc. 2020, 21, 1525–1532. [Google Scholar] [CrossRef]
- Poupin, P.; N’diaye, D.; Chaumier, F.; Lemaignen, A.; Bernard, L.; Fougère, B. Management of COVID-19 in a French Nursing Home: Experiences from a Multidisciplinary Mobile Team. J. Frailty Aging 2021, 10, 1–4. [Google Scholar] [CrossRef]
- Blanco-Donoso, L.M.; Moreno-Jiménez, J.; Gallego-Alberto, L.; Amutio, A.; Moreno-Jiménez, B.; Garrosa, E. Satisfied as professionals, but also exhausted and worried!!: The role of job demands, resources and emotional experiences of Spanish nursing home workers during the COVID-19 pandemic. Health Soc. Care Community 2022, 30, e148–e160. [Google Scholar] [CrossRef]
- Mahoney, F.I.; Barthel, D.W. Functional evaluation: The Barthel Index. Md State Med. J. 1965, 14, 61–65. [Google Scholar]
- Bernabeu-Wittel, M.; Ollero-Baturone, M.; Moreno-Gaviño, L.; Barón-Franco, B.; Fuertes, A.; Murcia-Zaragoza, J.; Fernández-Moyano, A. Development of a new predictive model for polypathological patients. The PROFUND index. Eur. J. Intern. Med. 2011, 22, 311–317. [Google Scholar] [CrossRef]
- Janus, S.I.; Schepel, A.A.; Zuidema, S.U.; de Haas, E.C. How Typical is the Spectrum of COVID-19 in Nursing Home Residents? J. Am. Med Dir. Assoc. 2021, 22, 511–516. [Google Scholar] [CrossRef]
- Krone, M.; Noffz, A.; Richter, E.; Vogel, U.; Schwab, M. Control of a COVID-19 outbreak in a nursing home by general screening and cohort isolation in Germany, March to May 2020. Euro Surveill. 2021, 26, 2001365. [Google Scholar] [CrossRef]
- Bernadou, A.; Bouges, S.; Catroux, M.; Rigaux, J.C.; Laland, C.; Levêque, N.; Noury, U.; Larrieu, S.; Acef, S.; Habold, D.; et al. High impact of COVID-19 outbreak in a nursing home in the Nouvelle-Aquitaine region, France, March to April 2020. BMC Infect. Dis. 2021, 21, 198. [Google Scholar] [CrossRef]
- Fallon, A.; Dukelow, T.; Kennelly, S.P.; O’Neill, D. COVID-19 in nursing homes. QJM 2020, 113, 391–392. [Google Scholar] [CrossRef]
- Tan, L.F.; Seetharaman, S.K. COVID-19 outbreak in nursing homes in Singapore. J. Microbiol. Immunol. Infect. 2021, 54, 123–124. [Google Scholar] [CrossRef]
- McMichael, T.M.; Currie, D.W.; Clark, S.; Pogosjans, S.; Kay, M.; Schwartz, N.G.; Lewis, J.; Baer, A.; Kawakami, V.; Lukoff, M.D.; et al. Public Health–Seattle and King County, EvergreenHealth, and CDC COVID-19 Investigation Team. Epidemiology of Covid-19 in a long-term care facility in King County, Washington. N. Engl. J. Med. 2020, 382, 2005–2011. [Google Scholar] [CrossRef]
- Instituto de Salud Carlos III. Report on the Situation of COVID-19 in Spain. Report COVID-19 no 32. 21 May 2020. Available online: https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/INFORMES%20COVID-19%202022/Informe%20nº%20161%20Situación%20actual%20de%20COVID-19%20en%20España%20a%2030%20de%20diciembre%20de%202022.pdf (accessed on 4 January 2023).
- Panagiotou, O.A.; Kosar, C.M.; White, E.M.; Bantis, L.E.; Yang, X.; Santostefano, C.M.; Feifer, R.A.; Blackman, C.; Rudolph, J.L.; Gravenstein, S.; et al. Risk Factors Associated with All-Cause 30-Day Mortality in Nursing Home Residents With COVID-19. JAMA Intern Med. 2021, 181, 439–448. [Google Scholar] [CrossRef]
- Garibaldi, B.T.; Fiksel, J.; Muschelli, J.; Robinson, M.L.; Rouhizadeh, M.; Perin, J.; Schumock, G.; Nagy, P.; Gray, J.H.; Malapati, H.; et al. Patient Trajectories Among Persons Hospitalized for COVID-19: A Cohort Study. Ann. Intern. Med. 2021, 174, 33–41. [Google Scholar] [CrossRef]
- Trecarichi, E.M.; Mazzitelli, M.; Serapide, F.; Pelle, M.C.; Tassone, B.; Arrighi, E.; Perri, G.; Fusco, P.; Scaglione, V.; Davoli, C.; et al. Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. Sci. Rep. 2020, 10, 20834. [Google Scholar] [CrossRef]
- De Smet, R.; Mellaerts, B.; Vandewinckele, H.; Lybeert, P.; Frans, E.; Ombelet, S.; Lemahieu, W.; Symons, R.; Ho, E.; Frans, J.; et al. Frailty and Mortality in Hospitalized Older Adults With COVID-19: Retrospective Observational Study. J. Am. Med. Dir. Assoc. 2020, 21, 928–932. [Google Scholar] [CrossRef]
- Trevisan, C.; Del Signore, S.; Fumagalli, S.; Gareri, P.; Malara, A.; Mossello, E.; Volpato, S.; Monzani, F.; Coin, A.; Bellelli, G.; et al. Assessing the impact of COVID-19 on the health of geriatric patients: The European GeroCovid Observational Study. Eur. J. Intern. Med. 2021, 87, 29–35. [Google Scholar] [CrossRef]
- Bernabeu-Wittel, M.; Ternero-Vega, J.; Díaz-Jiménez, P.; Conde-Guzmán, C.; Martín, N.; Moreno-Gaviño, L.; Delgado-Cuesta, J.; Rincón-Gómez, M.; Giménez-Miranda, L.; Amuedo, N.; et al. Death risk stratification in elderly patients with covid-19. A comparative cohort study in nursing homes outbreaks. Arch. Gerontol. Geriatr. 2020, 91, 104240. [Google Scholar] [CrossRef]
- Hashan, M.R.; Smoll, N.; King, C.; Ockenden-Muldoon, H.; Walker, J.; Wattiaux, A.; Graham, J.; Booy, R.; Khandaker, G. Epidemiology and clinical features of COVID-19 outbreaks in aged care facilities: A systematic review and meta-analysis. EClinicalMedicine 2021, 33, 100771. [Google Scholar] [CrossRef]
- Temkin-Greener, H.; Guo, W.; Mao, Y.; Cai, X.; Li, Y. COVID-19 Pandemic in Assisted Living Communities: Results from Seven States. J. Am. Geriatr. Soc. 2020, 68, 2727–2734. [Google Scholar] [CrossRef]
- Amblàs-Novellas, J.; Gómez-Batiste, X. Clinical and ethical recommendations for decision-making in nursing homes in the context of the COVID-19 crisis. Med. Clin. 2020, 155, 356–359. [Google Scholar] [CrossRef]
- Ayalon, L.; Zisberg, A.; Cohn-Schwartz, E.; Cohen-Mansfield, J.; Perel-Levin, S.; Siegal, E.B.-A. Long-term care settings in the times of COVID-19: Challenges and future directions. Int. Psychogeriatr. 2020, 32, 1239–1243. [Google Scholar] [CrossRef]
- Sacco, G.; Foucault, G.; Briere, O.; Annweiler, C. COVID-19 in seniors: Findings and lessons from mass screening in a nursing home. Maturitas 2020, 141, 46–52. [Google Scholar] [CrossRef]
- García-Cabrera, L.; Pérez-Abascal, N.; Montero-Errasquín, B.; Cano, L.R.; Mateos-Nozal, J.; Cruz-Jentoft, A. Characteristics, hospital referrals and 60-day mortality of older patients living in nursing homes with COVID-19 assessed by a liaison geriatric team during the first wave: A research article. BMC Geriatr. 2021, 21, 610. [Google Scholar] [CrossRef]
- Blain, H.; Rolland, Y.; Benetos, A.; Giacosa, N.; Albrand, M.; Miot, S.; Bousquet, J. Atypical clinical presentation of COVID-19 infection in residents of a long-term care facility. Eur. Geriatr. Med. 2020, 11, 1085–1088. [Google Scholar] [CrossRef]
- Tobolowsky, F.A.; Bardossy, A.C.; Currie, D.W.; Schwartz, N.G.; Zacks, R.L.; Chow, E.J.; Dyal, J.W.; Ali, H.; Kay, M.; Duchin, J.S.; et al. Signs, Symptoms, and Comorbidities Associated With Onset and Prognosis of COVID-19 in a Nursing Home. J. Am. Med Dir. Assoc. 2021, 22, 498–503. [Google Scholar] [CrossRef] [PubMed]
- Beiting, K.J.; Huisingh-Scheetz, M.; Walker, J.; Graupner, J.; Martinchek, M.; Thompson, K.; Levine, S.; Gleason, L.J. Management and outcomes of a COVID-19 outbreak in a nursing home with predominantly Black residents. J. Am. Geriatr. Soc. 2021, 69, 1155–1165. [Google Scholar] [CrossRef] [PubMed]
- Casas-Rojo, J.M.; Antón-Santos, J.M.; Millán-Núñez-Cortés, J.; Lumbreras-Bermejo, C.; Ramos-Rincón, J.M.; Roy-Vallejo, E.; Artero-Mora, A.; Arnalich-Fernández, F.; García-Bruñén, J.M.; Vargas-Núñez, J.A.; et al. Características clínicas de los pacientes hospitalizados con COVID-19 en España: Resultados del Registro SEMI-COVID-19. Rev. Clin. Esp. 2020, 220, 480–494. [Google Scholar] [CrossRef] [PubMed]
- Romero, M.M.; Céspedes, A.A.; Sahuquillo, M.T.T.; Zamora, E.B.C.; Ballesteros, C.G.; Alfaro, V.S.-F.; Bru, R.L.; Utiel, M.L.; Cifuentes, S.C.; Longobardo, L.M.P.; et al. COVID-19 outbreak in long-term care facilities from Spain. Many lessons to learn. PLoS ONE 2020, 15, e0241030. [Google Scholar] [CrossRef]
Wave | Number of Residents | Number of Affected Residents a | Age of Affected Residents b | Gender of Affected Residents (Female) | Number of Deaths in Affected Residents c | Date of Outbreak Start | Days Until MP Started | |
---|---|---|---|---|---|---|---|---|
NH1 | 1 | 168 | 123 (73.2%) | 89 (83–91) | 93 (76%) | 29 (23.6%) | 17 March 2020 | 15 |
NH2 | 1 | 155 | 93 (60.0%) | 84 (78–88) | 69 (44.5%) | 23 (24.7%) | 23 March 2020 | 11 |
NH3 | 1 | 101 | 35 (34.7%) | 89 (84–93) | 28 (80%) | 6 (17.1%) | 25 March 2020 | 12 |
NH4 | 1 | 33 | 21 (63.6%) | 89 (83–90) | 15 (45%) | 3 (14.3%) | 26 March 2020 | 11 |
NH5 | 2 | 149 | 103 (69.1%) | 84 (78–89) | 65 (44%) | 21 (20.4%) | 6 September 2020 | 10 |
NH6 | 2 | 77 | 58 (75.3%) | 86 (82–99) | 53 (68%) | 10 (17.2%) | 7 September 2020 | 11 |
NH7 | 2 | 118 | 50 (42.4%) | 80 (75–87) | 50 (100%) | 3 (6.0%) | 2 October 2020 | 6 |
NH8 | 2 | 69 | 11 (15.9%) | 88 (83–91) | 6 (54.5%) | 2 (18.2%) | 6 October 2020 | 21 |
NH9 | 2 | 130 | 33 (25.4%) | 83 (71–89) | 24 (73%) | 5 (15.2%) | 7 October 2020 | 19 |
NH10 | 2 | 57 | 32 (56.1%) | 86 (82–90) | 27 (84%) | 14 (43.8%) | 1 November 2020 | 3 |
NH11 | 2 | 104 | 11 (10.6%) | 82 (79–90) | 7 (64%) | 2 (18.2%) | 3 November 2020 | 11 |
NH12 | 3 | 38 | 17 (44.7%) | 87 (84–92) | 17 (100%) | 5 (29.4%) | 25 January 2021 | 1 |
TOTAL | 1199 | 587 (49%) | 86 (79–90) | 454 (77%) | 123 (21.0%) |
Clinical Characteristics | Global (N = 587) | Residents with COVID-19 Diagnosed before MP (N = 295) | Residents with COVID-19 Diagnosed during MP (N = 292) | p |
---|---|---|---|---|
Mean (SD)/Median [Q1–Q3]/No. (%) | ||||
Age | 86 (79–90) | 86 (80–91) | 85 (78–90) | 0.124 |
Female gender | 454 (77.3%) | 218 (73.9%) | 236 (80.8%) | 0.049 |
Comorbidities per patient | 4 (3–6) | 4 (3–6) | 4 (3–6) | 0.859 |
Principal comorbidities | ||||
Hypertension | 432 (73.7%) | 223 (75.9%) | 209 (71.6%) | 0.24 |
Dyslipidemia | 224 (38.2%) | 115 (39%) | 109 (37.3%) | 0.68 |
Advanced dementia | 220 (37.5%) | 111 (37.6%) | 109 (37.3%) | 0.94 |
Osteoarthritis causing affected BADL | 171 (29%) | 78 (26.4%) | 93 (31.8%) | 0.149 |
Diabetes mellitus | 149 (25.4%) | 75 (25.4%) | 74 (25.3%) | 0.982 |
Mild–moderate dementia | 130 (22.1%) | 67 (22.8%) | 63 (21.6%) | 0.724 |
NL disease with severe impairment | 130 (22.1%) | 52 (17.6%) | 78 (26.7%) | 0.008 |
Depression | 117 (19.9%) | 63 (21.4%) | 54 (18.5%) | 0.385 |
Atrial fibrillation | 98 (16.7%) | 53 (18.0%) | 45 (15.4%) | 0.407 |
Cerebrovascular disease | 92 (15.7%) | 47 (15.9%) | 45 (15.4%) | 0.862 |
Chronic heart failure | 73 (12.4%) | 39 (13.2%) | 34 (11.6%) | 0.563 |
COPD or asthma | 63 (10.7%) | 34 (11.5%) | 29 (9.9%) | 0.533 |
Obesity | 65 (11.1%) | 32 (10.8%) | 33 (11.3%) | 0.861 |
Hypothyroidism | 63 (10.7%) | 28 (9.5%) | 35 (12%) | 0.322 |
Anxiety disorders | 62 (10.6%) | 24 (8.1%) | 38 (13%) | 0.055 |
Coronary artery disease | 55 (9.4%) | 38 (12.9%) | 17 (5.8%) | 0.003 |
Parkinson disease | 49 (8.3%) | 27 (9.2%) | 22 (7.5%) | 0.478 |
Advanced chronic kidney disease | 40 (6.8%) | 22 (7.5%) | 18 (6.2%) | 0.534 |
Basal Barthel’s index | 48.8 (32.5) | 47.8 (31.5) | 49.7 (33.3) | 0.503 |
PROFUND index | 7.9 (4.2) | 8.1 (4.5) | 7.8 (3.9) | 0.376 |
No. of chronically prescribed drugs | 7.2 (3.8) | 7.0 (3.8) | 7.4 (3.8) | 0.261 |
Patients with extreme polypharmacy (>10 drugs) | 118 (20.1%) | 55 (18.7%) | 63 (21.6%) | 0.375 |
Patient with complications | 252 (43%) | 147 (50%) | 105 (36%) | 0.001 |
Acute respiratory failure | 225 (38%) | 132 (45%) | 93 (32%) | 0.001 |
LRT bacterial infections | 81 (14%) | 37 (12.8%) | 44 (15.2%) | 0.411 |
Persistent or incidental delirium | 79 (13.5%) | 45 (15.5%) | 34 (11.7%) | 0.183 |
Immobility and “bedridden syndrome” | 75 (13%) | 40 (13.8%) | 35 (12.1%) | 0.536 |
Acute renal failure | 35 (6%) | 22 (7.6%) | 13 (4.5%) | 0.117 |
Oropharyngeal dysphagia | 30 (5%) | 16 (5.6%) | 14 (4.8%) | 0.686 |
Urinary tract infection | 26 (4.4%) | 12 (4.1%) | 14 (4.8%) | 0.682 |
Pressure ulcers | 24 (4.1%) | 13 (4.5%) | 11 (3.8%) | 0.677 |
Number of complications per patient | 1.04 (1.5) | 1.24 (1.6) | 0.8 (1.3) | 0.019 |
Parameter, No. (%) | Global (N = 587) | First Wave (N = 272) | Second and Third Waves (N = 315) |
---|---|---|---|
Most frequently performed medical actions | |||
Parenteral drugs | 317 (54%) | 124 (46%) | 193 (61%) |
Oxygen therapy | 257 (44%) | 114 (42%) | 143 (45%) |
Intravenous lines and fluids | 180 (31%) | 86 (32%) | 94 (30%) |
Point-of-care ultrasound | 50 (8.5%) | 22 (8%) | 28 (9%) |
Transfusion of blood products | 2 (0.3%) | 0 | 2 (0.3%) |
Most frequent treatment administered | |||
Low-molecular-weight heparin | 305 (52%) | 118 (43%) | 187 (59%) |
Antimicrobials | 159 (27%) | 69 (25%) | 90 (29%) |
Corticosteroids | 172 (29%) | 55 (20%) | 117 (37%) |
Patients proposed for active standard care | |||
Antiviral treatment | 261 (44%) | 139 (51%) | 187 (59%) |
FIRST WAVE | |||
Hydroxychloroquine (HCQ) | 109 (78%) | ||
HCQ plus Lopinavir/Ritonavir (LPV/RTV) | 18 (13%) | ||
HCQ plus azithromycin | 11 (8%) | ||
SECOND WAVE | |||
Low-molecular-weight heparin | 187 (59%) | ||
Dexamethasone | 109 (19%) | ||
Dexamethasone plus remdesivir | 8 (1.4%) | ||
Remdesivir | 5 (1%) |
Parameter, Mean (SD)/Median [Q1–Q3]/No. (%) | Global (N = 587) | Residents with COVID-19 Diagnosed before MP (N = 295) | Residents with COVID-19 Diagnosed during MP (N = 292) | p | |
---|---|---|---|---|---|
Outcomes | |||||
Composite endpoint * | 525 (89.4%) | 245 (83%) | 280 (96%) | <0.001 | |
Survival | 464 (79%) | 218 (74%) | 246 (84%) | 0.002 | |
Patients transferred to hospital | 97 (16.5%) | 66 (22.4%) | 31 (10.6%) | <0.001 |
Patients That Survived | |||||
---|---|---|---|---|---|
Mean (SD)/Median [Q1-Q3]/No. (%) | |||||
Yes | No | p | Odds Ratio, IC | ||
Age | 87 (11) | 89 (8) | <0.001 | 1.066 (1.037–1.096) | |
Basal Barthel Index | 60 (50) | 35 (48) | <0.001 | 0.974 (0.966–0.982) | |
Profund scale | 7 (6) | 9 (4) | <0.001 | 1.152 (1.094–1.214) | |
Presence of symptoms | 295 (71.3%) | 169 (97.1%) | <0.001 | 1.509 (1.397–1.631) | |
Fever | 150 (65%) | 312 (88%) | <0.001 | 2.012 (1.674–2.418) | |
Cough | 104 (62.3%) | 358 (85.4%) | <0.001 | 2.257 (1.772–2.875) | |
Dyspnea | 108 (53%) | 354 (92.4%) | <0.001 | 3.277 (2.706–3.969) | |
Anorexia | 79 (61%) | 383 (84%) | <0.001 | 2.358 (1.758–3.163) | |
Delirium | 50 (46.3%) | 413 (86.4%) | <0.001 | 4.367 (3.165–6.024) | |
Global deterioration | 130 (57%) | 333 (93%) | <0.001 | 2.843 (2.398–3.372) | |
Main biological parameters | |||||
Lymphocytes (no./µL) | 1263.3 (162.3) | 1190 (712.3) | 0004 | 0.999 (0.998–1.000) | |
CRP | 67.2 (53.7) | 103.5 (80) | <0.001 | 1.014 (1.010–1.019) | |
Ferritin (ng/mL) | 456.4 (161.4) | 639 (413.5) | <0.001 | 1.001 (1.001–1.002) | |
Leukocytes (no./µL) | 7968 (2309.5) | 9169.1 (4782.4) | 0.02 | 1.000 (1.000–1.000) | |
Creatinine (mg/dL) | 1.3 (0.47) | 1.36 (1.1) | 0.028 | 1.311 (1.013–1.694) | |
ASAT | 26.1 (7.8) | 40 (26.2) | <0.001 | 1.046 (1.029–1.064) | |
ALAT | 21.2 (6.8) | 32.8 (26.2) | <0.001 | 1.047 (1.028–1.067) | |
Creatinine kinase | 116.3 (70.4) | 159.5 (122) | <0.001 | 1.006 (1.003–1.008) |
Composite Endpoint of Survival or Optimal End-of-Life Care (SOPC) | ||||
---|---|---|---|---|
Prognostic Factors | Adjusted Or | CI | p Value | |
Lack of cerebrovascular disease comorbidity | 3.9 | 1.2–12.1 | 0.02 | |
Inclusion in MP | 3.4 | 1.6–7.2 | 0.001 | |
Absence of dyspnea | 3.1 | 1.3–7 | 0.008 | |
Better PROFUND index | 0.94 | 0.9–1.0 | 0.05 | |
Lack of complications | 0.93 | 10–836 | <0.001 | |
Receiving low-molecular-weight heparin | 0.27 | 0.13–0.55 | <0.001 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Baron-Franco, B.; Ollero-Baturone, M.; Ternero-Vega, J.E.; Nieto-Martín, M.D.; Moreno-Gaviño, L.; Conde-Guzmán, C.; Gutiérrez-Rivero, S.; Rincón-Gómez, M.; Díaz-Jiménez, P.; Muñoz-Lopez, J.J.; et al. Survival Impact of an On-Site Medicalization Program in the Control of COVID-19 Outbreaks in 11 Nursing Homes. J. Clin. Med. 2023, 12, 6517. https://doi.org/10.3390/jcm12206517
Baron-Franco B, Ollero-Baturone M, Ternero-Vega JE, Nieto-Martín MD, Moreno-Gaviño L, Conde-Guzmán C, Gutiérrez-Rivero S, Rincón-Gómez M, Díaz-Jiménez P, Muñoz-Lopez JJ, et al. Survival Impact of an On-Site Medicalization Program in the Control of COVID-19 Outbreaks in 11 Nursing Homes. Journal of Clinical Medicine. 2023; 12(20):6517. https://doi.org/10.3390/jcm12206517
Chicago/Turabian StyleBaron-Franco, Bosco, Manuel Ollero-Baturone, Jara Eloísa Ternero-Vega, Maria Dolores Nieto-Martín, Lourdes Moreno-Gaviño, Concepcion Conde-Guzmán, Sonia Gutiérrez-Rivero, Manuel Rincón-Gómez, Pablo Díaz-Jiménez, Juan José Muñoz-Lopez, and et al. 2023. "Survival Impact of an On-Site Medicalization Program in the Control of COVID-19 Outbreaks in 11 Nursing Homes" Journal of Clinical Medicine 12, no. 20: 6517. https://doi.org/10.3390/jcm12206517
APA StyleBaron-Franco, B., Ollero-Baturone, M., Ternero-Vega, J. E., Nieto-Martín, M. D., Moreno-Gaviño, L., Conde-Guzmán, C., Gutiérrez-Rivero, S., Rincón-Gómez, M., Díaz-Jiménez, P., Muñoz-Lopez, J. J., Giménez-Miranda, L., Fernández-Nieto, C., & Bernabeu-Wittel, M. (2023). Survival Impact of an On-Site Medicalization Program in the Control of COVID-19 Outbreaks in 11 Nursing Homes. Journal of Clinical Medicine, 12(20), 6517. https://doi.org/10.3390/jcm12206517